X4 Pharmaceuticals (XFOR) Reports Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. MRVL

Go back to X4 Pharmaceuticals (XFOR) Reports Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia

X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)

November 13, 2024 6:01 AM EST

Mavorixafor durably and meaningfully elevated participants mean absolute neutrophil counts (ANC)

Mavorixafor enabled substantial reductions in G-CSF dosing while maintaining mean ANC at normal levels

Phase 2 study results and new analysis confirming functionality of neutrophils in sub-study participants bolster confidence in achieving success in Phase 3 4WARD trial

Company conference call and webcast today at 8:00 am ET

BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) --... More